Flatiron Health Raises $175M in Series C Funding
Summary
In conjunction with the funding, Daniel O’Day, chief operating officer, Roche Pharmaceuticals, will join Flatiron Health’s Board of Directors.Green, MD, vice president, Clinical Strategy and senior medical director, Flatiron Health provides the Flatiron Health OncologyCloud™ platform, which includes electronic medical record for oncology, analytics, patient portal and integrated billing management to deliver support for cancer care providers and life science companies.The company intends to use the funds to further invest in its software platform including enhancements across workflow optimization, infrastructure and design, new additions to value-based care solutions portfolio, designed to enable providers to participate in initiatives such as the Oncology Care Model (OCM) and other alternative payment models, release of tools and services to further support providers focused on clinical transformation.In addition to the financing round, Roche will purchase a number of Flatiron Health’s life science offerings.The companies will also collaborate to accelerate clinical trials, advance personalized medicine and enhance patient care.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
